Stryker Rejuvenate and ABG II Hip Implant

The Stryker Rejuvenate and ABG II modular hip implant docket now shows just six pending actions, more than a decade after centralization and well past the large settlement program that resolved the bulk of claims over corrosion and fretting at the modular-neck junction of these implants. At this stage, funding availability is narrow by definition — this is a docket in its terminal phase, not one where a funder should expect to build meaningful portfolio volume.

What remains is most likely a small population of later-diagnosed revision cases or claims that fell outside the settlement program's eligibility parameters. Any funding decision here should start with understanding exactly why a given claim sits outside the resolved population, since that answer determines both the litigation path and the realistic timeline to resolution — a claim excluded on a technical eligibility basis behaves very differently than one still working through initial diagnosis and causation development.

Medical-lien considerations remain relevant for any of these remaining claims given the revision-surgery costs typically associated with modular hip-implant failure, and a funder should model that lien exposure specifically rather than relying on the broader settlement program's historical averages, since the remaining claims by definition did not fit the standard pattern.

Given how few actions remain, single-case evaluation rather than portfolio-scale inventory finance is the appropriate structure. A funder should also expect the diligence timeline itself to run longer than for a fresh filing, since establishing eligibility for a claim sitting outside a completed settlement program typically requires reconstructing medical and procedural history that a standard intake file would not automatically capture. Criterica Capital's mass-tort finance line, together with medical-lien receivables financing where relevant, is built to underwrite exactly this kind of individual, late-stage claim.

Criterica Intelligence also maintains a structural brief on how this docket's settlement program was structured and what claim types it did not cover.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.